Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 3Recurrence 2Prostatic Neoplasms 2Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Liposarcoma 1Hodgkin Disease 1Disease Progression 1Carcinoma in Situ 1Advanced Malignant Solid Tumors 1

Interventions

Pemetrexed 3mifamurtide 2lenvatinib 2dostarlimab 2belinostat 2Ifosfamide 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gemcitabine 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2vactosertib 1surufatinib 1sintilimab 1robatumumab 1ridaforolimus 1reolysin 1pembrolizumab 1pazopanib 1omburtamab I-131 1niraparib 1isophosphamide mustard 1fludarabine 1endostar protein 1dinutuximab 1copanlisib 1cc-486 1cabozantinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Osteosarcoma × Clinical Trials, Phase II as Topic × Clear all
NCT07357519 2026-05-01

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Lantheus Medical Imaging

Phase 1/2 Recruiting
55 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡